Londamocitinib

DB19190InvestigationalSmall molecule

Londamocitinib is under investigation in clinical trial NCT06020014 (Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-severe Asthma Uncontrolled on Medium-high Dose ICS-LABA).

Formula / weight: C₂₈H₃₁F₂N₇O₄S · 599.66 g/mol (avg)
Also known as: (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide · 1-piperazineacetamide, n-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-4-pyrimidinyl)-1h-indol-7-yl)-.alpha.-(methoxymethyl)-4-methyl-, (.alpha.r)-
Code names: AZD-4604

Resolves to

Compound

UNIIJAC34RRR7SCAS2241039-81-4ChEMBLCHEMBL4447181

Structure

InChIKeyJNUZADQZHYFJGW-JOCHJYFZSA-NSMILESCOC[C@@H](N1CCN(C)CC1)C(=O)NC1=C2NC=C(C2=CC=C1)C1=NC(NC2=CC=CC(=C2F)S(C)(=O)=O)=NC=C1F

Targets

P23458JAK1P52333JAK3O60674JAK2

What you can answer from here — as of April 23, 2025

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Londamocitinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account